LIF and age-related macular degeneration: The alternative pathway has also gained attraction as a therapeutic focus, with Factor B, Factor D, and MASP-3 inhibitors showing promise in PNH (70) and lupus nephritis (71), along with age-related macular degeneration, a neurodegenerative retinal condition (72, 73).